SCHEMBL14924092

SCHEMBL14924092

CC(C)c1ccc(OCCN2CCN(C)CC2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.48
▸ LMNA P02545 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ LTA4H P09960 1/20 0.47
▸ HTR1B P28222 1/20 0.46
▸ BCHE P06276 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ TLR7 Q9NYK1 1/20 0.43
▸ HTR7 P34969 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ NOS3 P29474 1/20 0.42
▸ NOS1 P29475 1/20 0.42
▸ NOS2 P35228 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ PSMB1 P20618 1/20 0.42
▸ PSMB5 P28074 1/20 0.42
▸ USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13239766 0.90 SMN1; SMN2 (0.69) HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL20437917 0.89 SMN1; SMN2 (0.67) HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL20444420 0.87 SMN1; SMN2 (0.54) HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL14269837 0.87 SMN1; SMN2 (0.54) HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL19731505 0.84 HTT (0.60) HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL13239746 0.83 ALDH1A1 (0.63) HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL14924481 0.82 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1LTA4HHTR1BTLR7
SCHEMBL8245722 0.82 LTA4H (0.54) HTTSMN1; SMN2ALDH1A1LTA4HHTR1B
SCHEMBL12005829 0.81 TLR7 (0.49) SMN1; SMN2ALDH1A1LMNALTA4HHTR1B
SCHEMBL20374404 0.80 SMN1; SMN2 (0.73) HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 — — US disclosed
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 — — US disclosed
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2016-08-11 — — US disclosed
US-9345719-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2016-05-24 — — US disclosed
US-8957065-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD (KR) 2015-02-17 — — US disclosed
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2015-02-12 — — US disclosed
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD. (KR) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, LTK, FYN HTT 4145/4885SMN1; SMN2 3453/4885ALDH1A1 3955/4885
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 HTT 4208/4885SMN1; SMN2 3653/4885ALDH1A1 3912/4885
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 HTT 4208/4885SMN1; SMN2 3653/4885ALDH1A1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback